Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The fact that we were covering our cost base anyway during the last year means improved profits this year. Anybody got predictions about divvy's being announced?
A delayed reaction might be a slight mention in the 1st half of next year and and an actual one announced on full year '23? or even, dare to dream, a divvy announced this year!
ooofffttt72. Two things
1. Short of torture there is no way to 'force' an answer. That was not my point. I used the word 'press'. If you were genuinely interested in your question being answered you could have pursued it.
2. I quote from your post.
"Repeat business from previous clients / customers. According to time scales in the RNS’s that work has been concluded. Hence previous not current! "
Unfortunately I'm not quite sure your point here?
Hi Stas20. You've obviously done a fair bit of research but I'm not to sure of the interpretation and I quote from your 11.22 post.
" How else do you justify the 6 months of massive sales yet not one disclosure. Just as an example and these are really just a fraction of the sales, just the larger ones"
I've just done a quick calculation and the figures you give add up to 1 Mill as Buys, 5.45 Mill as sales and 20 Mill as unknowns? The reality could be anything I reckon!
Thanks for the link GLT. Yes it is worth a read - It's very comprehensive. For me the low SP is a mystery but as I've said before once we show that our core business can replace the Covid revenues then the SP will rise. The half year figures to September are going to be all important this year.
ooofffttt72 "The points raised below were submitted to the company. Only JM can tell you why he did not respond."
And only you can say why you didn't press him for an answer?
According to the announcements we have more repeat business than one off contracts and those one offs may well repeat anyway. The overall picture is upward progress from one customer to many .
Exactly right Laura, Those questions should have been put directly to JM at the presentation but he failed to do so because basically he's an attention seeker - just like the Donald!
Apart from last year, when we were adversely effected by Covid, we've made continuously excellent progress across the board since his JM's arrival. As he said in the presentation - when he came here we were basically a one customer company and we now have a growing range of both large and small companies that usually come back for more which is testament to the product and the efficiency of the company.
Article on page 4 of yesterdays Times. Professor Kristian Helin the CEO of the Institute of Cancer Research is leading a call for all Cancer patients to have both their own DNA tests and also their Tumors DNA tested to improve drug selection and also dosage levels. Signatories include Cancer Research UK and the British Pharmaceutical Association. Apparently the NHS is currently partially doing this but not routinely. Sounds right up PYC's street!
The current SP gives us an MC of some 2.5 Mill so the cash situation is some 25% of that. We've never been in such a forward positive situation as this before. Did a little top-up this morning and bought at 2.5950p which is (I hope!) a bargain!
I quite like the way JM has gone about growing PYC. Very similar to his webcasts. Nothing showy but to me he sees pretty determined and gives strait forward facts and figures. As Laura posted - add in almost 2 years of cash and what's not to like?
Some good projections there GLT and a good chance of them coming good I reckon. I too was impressed by the agility displayed by YGEN to cope with Covid and it looks as if the revenues from that have been well invested. I've said before that I think that the SP will improve once we've demonstrated our ability to grow revenues without Covid. This financial year is going to be important and as you say we've never been in such a good position as we are in right now.
Yes, It's just I'm a little impatient! We did 7 Mill in the last two half years and made a profit to boot. Any increase in revenue should have a biggish impact on the profit because of our largely fixed costs. Should be worth the wait though.
A little surprised about the lack of activity here but to be fair the webcast was " steady as it goes". I have every confidence
in the future years so yes we are, not future proofed, but future fruitful.
Hemo, Don't roll LR's head. We are now starting to deliver. Everything is now in place. The big focus is on the States but our UK/European business is building very nicely thanks.
The short term contracts we announce are our bed and butter but with the Partner study and the Val projects we are beginning to widen our horizons. The ongoing contracts with existing customers seem to be holding up well and we are also adding new customers. I believe revenues will definitely increase.
I think it's steady as we go with the Val project more likely to succeed than not - no guarantees though!
Is it just me not seeing it or have we not had one? Not sure why - it must be positive?
John, You are correct in that GS is sincere, and I think you may have underrated that quality. You are wrong that he is very very dim. If that were so he would not have been able to negotiate the no fee no win with Dentons which was quite complex involving certain upfront fees that were not payable by Fox. In addition Sir Mark Grant would not have become a NED - You need to read his CV as in the RNS.
We doubled our revenue last year. The SP will depend on how quickly we replace the Covid revenue with our core product revenue. We now have a presence in the USA which is the largest health care market in the world and with over 100 products to sell. The April update was promising and we've got until March to deliver. When we get the accounts my focus will be on the 1st quarters update. This is definitely a totally different company from the old one trick pony that was NIPT. It was, and is, a good trick mind but we are now unrecognisable.
Pretty much steady as she goes. Growth is steady with new customers and we seem to often get repeat business from new contracts. VAL and the PARTNER study both progressing. No fireworks but in this day and age steady is good!
Hi KingHomer, Siennaj isn't exactly friendly in the responses - almost dismissive and rude to boot. I'm tempted to ignore them in the future, there's nothing to gain by reading them - possibly even the green box!
Hi Siennaj, I think your a little pessimistic re Val. Our chances of success are well over 50% I reckon. If your that concerned you could ask JM for an update in Wednesday's Investor meeting?
The SP is a disappointment but look at the recent international performances of both primary and secondary stock markets - YGEN is not alone!
We doubled our revenue last year with Covid testing. The future SP will depend on how quickly we can replace that income.
We appear to have an unique NIPT 'Ranger' advantage into the USA. This is the worlds biggest healthcare market and we have over a hundred other products to follow that unique inroad. Scott Sargent will not let us miss a trick in the USA.
Our 'core' products have increasing sales - what's not to like?